R&D teams value the opportunity to discuss their science with board directors who understand both its technical substance and its business implications.
That has been my experience as a public- and private-company director, a physician-scientist and an industry advisor. The best conversations are neither technical show-and-tell nor a full-scale interrogation by the board. They occur when people who understand science and business examine what the evidence means for strategy: which platform merits investment, which uncertainty can be tolerated, what would change a decision and when a claim or acquisition rests on assumptions requiring more testing.
When directors engage with the substance and its commercial implications, scientists know their work is taken seriously at the highest level. They receive questions and feedback beyond the management chain; directors gain a clearer view of the science’s promise and limitations.
For CEOs, this is an underutilized opportunity. The board does not manage experiments or choose assays. It approves major investments and acquisitions, oversees risk and holds management accountable for the company’s direction. A company can build a formidable R&D organization without connecting it effectively to that board. It may then fail to get full value from either its science or its directors.
This question also grew out of my recent analysis, “The Changing Landscape of Science Published by a Cross-Section of 15 Leading Beauty Companies, 2015–2025.” That study documented a changing research landscape; the question here is whether boards are equipped to understand what that science means for the business.
What the Public Record Shows
I examined public disclosures from 15 leading beauty and personal-care companies for which science materially affects the business and for which enough information was available to evaluate governance. The group is deliberately varied; it is not a ranking or statistical sample. For this analysis, a nonexecutive director is a board member who does not manage the company day to day. In companies with employee representation on the board, I counted only directors occupying shareholder-elected board seats. Using disclosures available through October 8, 2026, I assessed relevant capability among those directors, any explicit board mandate for science or R&D, any dedicated committee, and other disclosed routes by which science reaches the board. To avoid confusing sparse disclosure with weak oversight, I also asked whether each company described other complex board responsibilities more fully.
My definition of “direct scientific capability” required scientific training applied through substantive work relevant to beauty. “Science-governance experience” required sustained responsibility for consequential decisions involving science-dependent products, pipelines, technologies, licenses, acquisitions or investments. A technical degree, senior title or generic beauty, consumer, investment or technology experience did not qualify by itself.
Among the 125 nonexecutive directors reviewed, only 16 (about 13%) had either direct, relevant scientific capability or experience governing science-dependent decisions. But only three of the 15 companies had even one shareholder-side nonexecutive director with direct, relevant scientific experience; 12 had none.
P&G alone disclosed a dedicated board Innovation & Technology Committee, with a named senior R&D liaison. Other structures can work. Kao explicitly assigns science-to-innovation and value oversight to the full board. Unilever disclosed a full-board R&D strategy and pipeline review together with an R&D-center visit. Beiersdorf requires R&D experience in its Supervisory Board profile and has described R&D education, onboarding and deep dives for directors. In September 2026, a Shiseido outside director described increasing Board attention to R&D value creation, research-theme selection and the use of technology across brands.
Several companies disclose standing scientific advisory boards; many others convene brand- or project-specific panels. These can be valuable operating resources, yet I found no public disclosure of even one scientific advisory body appointed by, formally reporting to or routinely presenting to the company’s board of directors. Management may nevertheless share scientific advisory board deliberations or conclusions with directors. Table 1 maps what companies make publicly visible.
| Company | Non-Executive Directors Meeting Either Criterion | Dedicated Board Science/Technology Committee | Other Disclosed Path from Science or External Advisers to the Board |
|---|---|---|---|
| Amorepacific | Two | No | Scientific boards disclosed at brand/laboratory level; no route to the board of directors identified |
| Beiersdorf | Two | No | R&D required in Supervisory Board profile; director education, onboarding and deep dives disclosed |
| Coty | None identified | No | Board receives at least annual sustainability updates; skincare scientific advisory board advises R&D; no R&D-specific route to the board identified |
| e.l.f. Beauty | None identified | No | No recurring science-specific route to board identified |
| Estée Lauder | One | No | Recurring specialist meetings and green-chemistry scientific advisory board; no route to the board of directors identified |
| Henkel | One | No | Research-group scientific advisory board supports operating science; no route to the Supervisory Board identified |
| Kao | One | No | Full-board oversight of the path from science to innovation and value is explicit; R&D experience is supplied by an executive director |
| L’Oréal | Three | No | Board skills inventory includes Research & Innovation (R&I); a historical R&I-facing scientific advisory board is disclosed, but no route to the board of directors is identified |
| Natura | One | No | No recurring science-specific board route identified |
| ODDITY Tech | None identified | No | AI, data science and molecular discovery are strategic; no independent science-review route identified |
| P&G | Two | Yes | Committee has named R&D liaison and a broad technical/innovation mandate |
| POLA ORBIS | None identified | No | Board matrix locates R&D capability among executive directors |
| Puig | Two | No | Strong technical, ingredients and science-business experience; formal pathway not identified |
| Shiseido | One | No | Outside directors now describe increasing full-board attention to R&D value creation, research-theme selection and technology-to-brand deployment |
| Unilever | None identified | No | Full-board R&D strategy/pipeline review and R&D-center visits disclosed |
Notes: “None/not identified” refers only to the public sources reviewed and is not evidence that no relevant discussion occurs. The director population comprises current shareholder-side non-executive directors: independent directors and directors representing significant shareholders, but not executives or employee representatives. Findings are as of October 8, 2026.
When the Record is Silent
Public filings can’t reveal every practice behind closed doors. A company’s silence about a science-governance mechanism does not mean that none exists, and limited disclosure is not proof of weak governance. But silence can still be informative. It may reflect different reporting requirements or simply a company’s preference for saying no more than it must.
However, reporting requirements do not fully explain the pattern. Even among publicly traded U.S. companies subject to the same federal disclosure requirements, I found substantial variation. Some made the board’s engagement with science visible; others did not.
Nor does a general preference for minimal disclosure fully explain the results. Several companies that did not identify a clear science-governance pathway
Dusan Petkovic at Adobe Stock
This asymmetry doesn’t prove that board oversight of science is absent. It is, however, a finding about visibility. Investors and other stakeholders cannot assess whether responsibility is clear or whether the board has the expertise and information needed to oversee science as a source of risk and long-term value. Better disclosure need not reveal proprietary research or pipeline information. It can identify where responsibility resides, how often the board engages and what kinds of scientific questions enter major decisions.
The Right Director and the Right System
Clinical experience can be valuable, but it isn’t the same as scientific fluency. A director who treats patients but has not conducted or governed relevant research may bring useful perspective without being equipped to interrogate methods, evidence and uncertainty. Scientific fluency means more than following a technical presentation. It allows a director to ask whether the experimental design and endpoint support the conclusion management wants the board to draw. The board therefore needs the right director, or combination of directors, to challenge the science and explain its business implications. That includes the choices management asks the board to make about investment, product claims and risks that could materially affect the company. It also includes understanding how requirements such as the U.S. Modernization of Cosmetics Regulation Act of 2022 (MoCRA), or changing ingredient and environmental rules in Europe, may alter R&D priorities, formulations, claims and investment needs. Management owns compliance; the board must oversee the consequences for strategy and company-wide risk.
That translation role matters. Every director need not be a scientist, just as every audit-committee member need not be an accountant. But the board needs enough fluency to recognize which assumptions deserve scrutiny and to understand the answers it receives.
A single expert, however distinguished, is not a governance system. I would look for three things.
- Capability: Some directors need more than scientific literacy. They need enough scientific fluency to test the evidence and enough business judgment to understand what it means for the company. Experience governing science matters but cannot always substitute for having done scientific work.
- Clear Responsibility: Oversight may sit with a dedicated board committee, another committee with an explicit mandate or the full board. The structure should fit the company, but responsibility shouldn’t be left implicit.
- Reliable Information: Boards need more than a polished portfolio summary. They need to understand the evidence, the important uncertainties, the alternatives considered and what has been learned from failure. That may require strategy reviews, deep dives on selected platforms, site visits, direct discussions with scientists, independent expert sessions or a defined route for scientific advisers to raise material issues.
The aim is not to inundate directors with laboratory detail. Direct contact with scientists should be arranged with management and should not create a reporting line around R&D leadership. Management and the board should design the arrangement together to improve decisions for which both are accountable. Companies will choose different models. What matters is whether the board has the expertise and access needed to engage with science when it becomes material to strategy.
A Two-Way Return
Good board engagement gives R&D more than visibility: it provides a different kind of challenge. Management reviews properly emphasize execution, budgets and milestones. Directors can ask how technical assumptions affect strategy, whether evidence supporting an acquisition justifies its price, or whether commercial enthusiasm obscures scientific risk.
The board, meanwhile, makes better decisions about the R&D budget and related capital commitments when it understands how R&D creates value. Progress is rarely linear. Negative findings and abandoned hypotheses can reflect disciplined learning rather than failure. Direct exposure to scientists and their reasoning helps directors distinguish productive uncertainty from avoidable risk.
Scientists need not turn a board presentation into a finance lecture. They should explain which results are decisive, what remains uncertain and how additional work could change the decision before the board. They can frame their work more effectively when they understand how the board chooses among competing investments and across the product portfolio. A healthy pathway runs in both directions: the board learns what the science can and cannot yet support, and R&D learns which uncertainties matter most to the business.
Orawan at Adobe Stock
What CEOs and R&D Leaders Can Do
CEOs and R&D leaders have to build this connection together. CEOs can ask whether the board has the expertise and access needed to contribute. In turn, R&D leaders can prepare scientists for these discussions by helping them explain the evidence in plain language without hiding uncertainty and by making clear what decision the board is being asked to make. With the general counsel or corporate secretary, they can identify which directors hear from scientists, where those conversations occur and whether they happen early enough to affect important decisions.
They can then establish a regular pattern suited to the company: perhaps an annual R&D strategy discussion, deep dives on selected platforms, site visits or periodic conversations with scientific teams. The board should also have access, when appropriate, to outside scientific advisors and the substance of important advisory deliberations. That might include minutes or a concise summary of a scientific advisory board meeting convened to evaluate a potential acquisition or consequential result. Scientists should hear how board questions affected a decision, and directors should hear what later evidence showed. That is how occasional contact becomes institutional learning.
CEOs should also consider whether future director appointments and committee assignments reflect the importance of science to the business. A scientific expert becomes useful when the role carries authority and access.
Beauty companies have spent decades building sophisticated scientific organizations. Connecting those organizations to directors who can understand and challenge their work can improve decisions and help the company get more from both its science and its board.
